| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Email: |
3003867561@qq.com |
| Products Intro: |
Product Name:RWJ-51204
CAS:205701-85-5
Purity:98% Package:5mg；10mg；20mg；50mg；100mg；200mg
|
RWJ-51204 manufacturers
- RWJ-51204
-
- $350.00 / 1mg
-
2024-11-19
- CAS:205701-85-5
- Min. Order:
- Purity: 99.57%
- Supply Ability: 10g
|
| | RWJ-51204 Basic information |
| Product Name: | RWJ-51204 | | Synonyms: | RWJ-51204;Pyrido[1,2-a]benzimidazole-4-carboxamide, 5-(ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-;RWJ51204,RWJ 51204;RWJ-51204, 10 mM in DMSO | | CAS: | 205701-85-5 | | MF: | C21H19F2N3O3 | | MW: | 399.39 | | EINECS: | | | Product Categories: | | | Mol File: | 205701-85-5.mol |  |
| | RWJ-51204 Chemical Properties |
| Boiling point | 533.0±50.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 10.81±0.70(Predicted) |
| | RWJ-51204 Usage And Synthesis |
| Uses | RWJ-51204 is a partial agonist of GABA(A) receptor, with Ki of 0.2-2 nM to the benzodiazepine site on GABA(A) receptors. | | in vivo | RWJ-51204 is orally active in anxiolytic efficacy tests. WJ 51204 dose-relatedly antagonizes PTZ-induced clonic convulsions when administered orally (ED50 = 0.04 mg/kg). RWJ-51204 is effective in the conflict test in monkeys (ED50 of approximately 0.5 mg/kg p.o.). RWJ-51204 potently impairs rotarod performance in rats (ED50 = 0.12 mg/kg), and all rats given RWJ-51204 orally at 30 mg/kg exhibit sedation, reduced skeletal muscle tone, and impairment of rotarod performance. | | References | [1] Dubinsky B, et al. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90. DOI:10.1124/jpet.102.036954 |
| | RWJ-51204 Preparation Products And Raw materials |
|